EGFR and lung carcinoma: In a recent study by Guo et al., the authors found that aberrant activation of the EGFR signaling pathway downregulated miR-145 expression in NSCLC, an addition of EGFR inhibitor AG1478 that could restore the expression of miR-145 in lung cancer cells [27].